» Articles » PMID: 38140020

In-Line Aerosol Therapy Via Nasal Cannula During Adult and Paediatric Normal, Obstructive, and Restrictive Breathing

Overview
Journal Pharmaceutics
Publisher MDPI
Date 2023 Dec 23
PMID 38140020
Authors
Affiliations
Soon will be listed here.
Abstract

High-flow nasal oxygen therapy is being increasingly adopted in intensive and home care settings. The concurrent delivery of aerosolised therapeutics allows for the targeted treatment of respiratory illnesses. This study examined in-line aerosol therapy via a nasal cannula to simulated adult and paediatric models with healthy, obstructive and restrictive lung types. The Aerogen Solo vibrating mesh nebuliser was used in combination with the Inspired O2FLO high-flow therapy system. Representative adult and paediatric head models were connected to a breathing simulator, which replicated several different states of lung health. The aerosol delivery was quantified at the tracheal level using UV-spectrophotometry. Testing was performed at a range of supplemental gas flow rates applicable to both models. Positive end-expiratory pressure was measured pre-, during and post-nebulisation. The increases in supplemental gas flow rates resulted in a decrease in aerosol delivery, irrespective of lung health. Large tidal volumes and extended inspiratory phases were associated with the greatest aerosol delivery. Gas flow to inspiratory flow ratios of 0.29-0.5 were found to be optimum for aerosol delivery. To enhance aerosol delivery to patients receiving high-flow nasal oxygen therapy, respiratory therapists should keep supplemental gas-flow rates below the inspiratory flow of the patient.

Citing Articles

A potential therapeutic strategy based on acute oxidative stress induction for wild-type NRF2/KEAP1 lung squamous cell carcinoma.

Sanchez-Ortega M, Garrido A, Cirauqui C, Sanz-Gonzalez L, Hernandez M, Gonzalez-Garcia A Redox Biol. 2024; 75:103305.

PMID: 39137583 PMC: 11372719. DOI: 10.1016/j.redox.2024.103305.


Performance Characterisation of the Airvo2 Nebuliser Adapter in Combination with the Aerogen Solo Vibrating Mesh Nebuliser for in Line Aerosol Therapy during High Flow Nasal Oxygen Therapy.

MacLoughlin R, Mac Giolla Eain M Pharmaceutics. 2024; 16(4).

PMID: 38675226 PMC: 11053618. DOI: 10.3390/pharmaceutics16040565.


Towards More Precise Targeting of Inhaled Aerosols to Different Areas of the Respiratory System.

Sosnowski T Pharmaceutics. 2024; 16(1).

PMID: 38258107 PMC: 10818612. DOI: 10.3390/pharmaceutics16010097.

References
1.
Li J, Tu M, Yang L, Jing G, Fink J, Burtin C . Worldwide Clinical Practice of High-Flow Nasal Cannula and Concomitant Aerosol Therapy in the Adult ICU Setting. Respir Care. 2021; 66(9):1416-1424. DOI: 10.4187/respcare.08996. View

2.
Calabrese C, Annunziata A, Mariniello D, Allocca V, Imitazione P, Cauteruccio R . Aerosol delivery through high-flow nasal therapy: Technical issues and clinical benefits. Front Med (Lausanne). 2023; 9:1098427. PMC: 9889634. DOI: 10.3389/fmed.2022.1098427. View

3.
Rygg A, Longest P . Absorption and Clearance of Pharmaceutical Aerosols in the Human Nose: Development of a CFD Model. J Aerosol Med Pulm Drug Deliv. 2016; 29(5):416-431. PMC: 8662553. DOI: 10.1089/jamp.2015.1252. View

4.
Xi J, Si X, Longest W . Electrostatic charge effects on pharmaceutical aerosol deposition in human nasal-laryngeal airways. Pharmaceutics. 2014; 6(1):26-35. PMC: 3978523. DOI: 10.3390/pharmaceutics6010026. View

5.
Dailey P, Harwood R, Walsh K, Fink J, Thayer T, Gagnon G . Aerosol Delivery Through Adult High Flow Nasal Cannula With Heliox and Oxygen. Respir Care. 2017; 62(9):1186-1192. DOI: 10.4187/respcare.05127. View